Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas

Fig. 1

Expression of TAGLN2 is associated with tumor grade in gliomas. a Quantification of TAGLN2 mRNA expression levels in gliomas in TCGA, Rembrandt, and CGGA datasets. b Quantification of GBM subtype-specific TAGLN2 expression in TCGA and GSE4271 datasets. Log2-transformed expression of TAGLN2 mRNA levels are listed on the Y-axis. Error bars represents the SEM. c ROC curve showing sensitivity of TAGLN2 as a marker to distinguish mesenchymal subtype GBM from non-mesenchymal subtype GBM patients. d Representative images of IHC staining for TAGLN2 in different grade gliomas and normal brain specimens. Magnification: ×200, upper; ×400, lower. e The prognostic significance of TAGLN2 expression in LGG and GBM patients was analyzed in TCGA (n = 667) database. The cut-off level was set at the median value of the TAGLN2 levels. *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page